Understanding prostate cancer risk in the use of 5-alpha reductase inhibitors

Authors

Teemu Murtola

Published Date

September 2017

DOI

https://doi.org/10.18591/BJUIK.0006

Access E-Learning

Cookie preferences

This site makes use of cookies to help improve our understanding of how you use the site. This information does not directly identify you, but because we respect your right to privacy, you can choose not to allow some types of cookies.